Boston Scientific Corp (BSX)vsCytek Biosciences Inc (CTKB)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
CTKB
Cytek Biosciences Inc
$4.63
-1.70%
HEALTHCARE · Cap: $575.90M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 9863% more annual revenue ($20.07B vs $201.49M). BSX leads profitability with a 14.4% profit margin vs -33.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
CTKB
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for CTKB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
BSX profiles as a growth stock while CTKB is a turnaround play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.31 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 41/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, providing state-of-the-art cell analysis solutions to the life sciences industry. The company's advanced technologies facilitate comprehensive cellular analyses that are crucial for research in immunology, cancer diagnostics, and drug development. With a commitment to innovation and excellence in customer service, Cytek has solidified its status as a key contributor in the biotechnology sector, addressing the growing need for precise cell analysis tools. Boasting a diverse product portfolio and a robust market position, the company continues to drive advancements in the rapidly evolving field of cell biology research.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?